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Abstract
Cone photoreceptors mediate visual acuity under daylight conditions, so loss of cone-mediated central vision of course
dramatically affects the quality of life of patients suffering from retinal degeneration. Therefore, promoting cone survival has
become the goal of many ocular therapies and defining the stage of degeneration that still allows cell rescue is of prime
importance. Using the Rpe65R91W/R91W mouse, which carries a mutation in the Rpe65 gene leading to progressive
photoreceptor degeneration in both patients and mice, we defined stages of retinal degeneration that still allow cone
rescue. We evaluated the therapeutic window within which cones can be rescued, using a subretinal injection of a lentiviral
vector driving expression of RPE65 in the Rpe65R91W/R91W mice. Surprisingly, when applied to adult mice (1 month) this
treatment not only stalls or slows cone degeneration but, actually, induces cone-specific protein expression that was
previously absent. Before the intervention only part of the cones (40% of the number found in wild-type animals) in the
Rpe65R91W/R91W mice expressed cone transducin (GNAT2); this fraction increased to 64% after treatment. Correct S-opsin
localization is also recovered in the transduced region. In consequence these results represent an extended therapeutic
window compared to the Rpe65-/- mice, implying that patients suffering from missense mutations might also benefit from a
prolonged therapeutic window. Moreover, cones are not only rescued during the course of the degeneration, but can
actually recover their initial status, meaning that a proportion of altered cones in chromophore deficiency-related disease
can be rehabilitated even though they are severely affected.
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Introduction
Two main factors compose the success of a therapy: the
efficiency of the therapeutic strategy and the status of the cells to
save. As good as the treatment can be, it will never offer its full
action if it is applied too late in the natural course of the disease.
Thus the detailed description of the disease progression is of prime
importance to determine the latest stage that can be targeted for
success of the treatment before irreversible damage. Extensive
technological advances in therapies and imaging now offer a large
panel of possibilities to heal ophthalmologic diseases that were so
far incurable.
Gene therapy has found in ophthalmology the advantage of a
field that includes many different monogenic hereditary diseases of
a relatively accessible organ, offering scientists a rich ground to
develop different strategies of gene therapy. Confirming the
dynamism in this field, RPE65 gene replacement for Leber
congenital amaurosis (LCA) [1] is now in Phase I/II clinical trials
driven by three different teams all using AAV2/2 vectors [2–5].
Most gene transfer studies show success only when the treatment
was applied early or even before the onset of the degeneration. In
consequence, it is still unclear whether cones can recover a normal
state when treatment occurs during advanced stages of cone
degeneration. In many models of retinal degeneration, rods die
first, and the following lack of trophic support as well as the
alteration in the architectural structure, induces cone death. Thus
cone rescue and rehabilitation can not be evaluated in such models
because cone survival will inevitably be impaired in these affected
retinas. From this point of view, Rpe65-deficient mice are
interesting models to study cone degeneration, since in this case
cone loss occurs before rod loss [6]. RPE65 is expressed in the
retinal pigment epithelium [7], which is juxtaposed to the
neuroretina. This protein belongs to the visual cycle, and is
responsible for the regeneration of 11-cis-retinal, the chromophore
essential for the visual pigments (contained in rod and cone
photoreceptors) to capture light. Deletion of the RPE65 isomerase
blocks the generation of this retinoid resulting in a severe loss of
photoreceptor function as well as cone and rod death [7].
Conversely, the restoration of RPE65 expression allows to rescue
rod function and the proof of principle of this approach was widely
demonstrated in mouse [8–14] and dog models [15–17]. Cone
function can also be rescued after RPE65 gene transfer, but the
therapeutic window is very limited in RPE65 knockout mice which
undergo a rapid cone degeneration [13,18]. The first results of the
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Phase I clinical trials, started end of 2007, have shown no adverse
effects so far and even improvement of some visual functions in
certain cases [2–5,19]. These encouraging results lead to the
second step of these trials consisting in treating younger patients.
As in most progressive diseases, the time of intervention during
the disease progression determines the efficiency of the rescue [10].
Measurements of the retinal thickness in young RPE65-affected
patients revealed inter-individual differences not clearly related to
age [20], which might have a consequence on the efficiency of a
potential treatment. The general genetic background as well as
modifier genes influencing RPE65 function may be important
factors in the phenotypic variability [21]. Moreover, among the
patients suffering from RPE65 gene defects, more than half bear
missense mutations [22]. These mutations are extremely hetero-
geneous, thus residual enzyme activity can be expected in certain
cases which possibly explains the high variability of the disease
severity [23–26]. The R91W mutation was described in patients
suffering from an early-onset retinal degeneration [25], who
experience useful cone-mediated vision in the first decade of life
[26]. As suggested by this favorable condition in young patients, a
low level of the mutated protein is present and allows production
of small amounts of 11-cis-retinal in the Rpe65R91W/R91W mouse
model [27], where cone degeneration is observed but with slower
kinetics compared to the null background for RPE65 [28].
Indeed, in Rpe65-/- mice, cones rapidly degenerate in young
adults, resulting in an almost complete loss of cones at 8 weeks of
age [6]. Expression of cone transducin a-subunit (GNAT2) as well
as of both cone opsins (short- (S-) and middle-/long- (M/L-)
wavelength opsins) is already severely impaired at 1 month of age
[6]. Rods degenerate more slowly, with residual function
demonstrated up to 24 months [29]. Consistent with these
observations, we previously showed that, using lentiviral-mediated
RPE65 gene transfer, cone rescue in Rpe65-/- mice is limited to
injection at P5 and absolutely inefficient if the treatment occurs at
1 month [13]. The cones appear to be too severely affected at 1
month of age in Rpe65-/- mice to benefit from the revitalization of
the visual cycle. The reason for cone death is not yet fully
determined however there are now several reports suggesting that
the lack of 11-cis-retinal is the main cause for cone degeneration in
different mouse models (Lrat-/- [30,31], Irbp-/- [32]). Because in
Rpe65-/- mice the level of 11-cis-retinal is undetectable, cone opsin
mislocalization becomes evident early in life [28,33] and the cones
rapidly degenerate. Treatment with 9-cis-retinal [32,33] or gene
transfer of RPE65 [13] corrects the localization of the cone opsins
to the outer segments, thus demonstrating the important role of
11-cis-retinal for the accurate trafficking of the cone opsins and
cone survival. In RPE65-deficient patients, cone loss is observed in
both the fovea [34] and the periphery, which is mainly populated
by S-cones and first affected [35,36]. We thus took advantage of
the milder cone phenotype of the Rpe65R91W/R91W mouse model to
assess the time-frame limit for effective cone rescue and whether
gene therapy preserves only the remaining healthy cones or can
revitalize severely affected cones. Such knowledge should bring
broad applications to therapies aiming to rescue cones during the
course of their degeneration.
Results
Early LV-RPE65 treatment in Rpe65R91W/R91W mice
improves retinal function
A gene replacement strategy requires expression of the
therapeutic gene in the appropriate cell type. In order to target
the retinal pigment epithelium (RPE), we used a HIV-1 derived
lentiviral vector known to target RPE cells very efficiently [37,38].
Additionally, to restrict expression of the transgene in RPE, we
used a 0.8 kb fragment of the human RPE65 promoter (R0.8)
[13,39,40]. We thus restored expression of wild type RPE65 in
Rpe65R91W/R91W mice by intraocular injection in postnatal mice
(postnatal day 5, (P5), Fig S1A) or by subretinal injection in adult
mice of LV-RPE65 vector (Fig S1C). This vector drives specific
expression of the RPE65 protein in RPE although in rare cases the
LV-GFP control vector also drives expression in Mu¨ller cells as
described previously (Fig S1B, [13]). We can distinguish the
RPE65 transgene expression from the endogenous mutant protein
mostly because of an increased RPE65 immunostaining within the
RPE near the injection site (Fig S1C, arrow). The area of
transduction obtained was similar for injection both in P5 and in 1
month-old animals, ranging from 0.1 to 3 mm2 (Fig S1D, this
heterogeneity in the transduction area is due to the injection
procedure). The eyes with the wider zone of transduction have
thus around 20% of the retina expressing the wild type RPE65
protein.
In order to evaluate the efficiency of RPE65 gene transfer to
restore a retinal function, the electrical activity of the retina was
recorded by electroretinography (ERG) 1 month and 4 months
post injection at P5. A control group injected with a vector
containing a GFP reporter gene (LV-GFP) was examined in
parallel. As previously described [27], Rpe65R91W/R91W retinal
function in photopic conditions is recordable. The photopic
responses of Rpe65R91W/R91W mice showed no differences in
sensitivity, only a diminished b-wave amplitude with age
compared to wild type mice. This particular response is
hypothesized to be a mixed cone-rod response and renders the
impact of gene transfer on cone function difficult to assess.
Consistently, there was no difference in the photopic responses
between the LV-RPE65 group, the LV-GFP group, untreated
animals or wild type animals (data not shown). However,
Rpe65R91W/R91W mice have reduced sensitivity to the rod response
which can be measured in scotopic conditions with low intensity
stimuli. In LV-RPE65-treated eyes expressing RPE65, a 3-log
increase in the b-wave response threshold in the scotopic ERG
clearly showed that the rod system acquires an improved
sensitivity (Fig 1A). This improvement of scotopic sensitivity was
maintained over 3 more months corresponding to the end of the
experiment (Fig 1B) and the maximum b-wave amplitude was
80% of wild-type. Moreover, the b-wave shape at higher stimuli
was extended compared to LV-GFP or untreated animals, which
is characteristic of the cone input for these light intensities.
Notably, at 4 months of age, the a-wave (reflecting the
photoreceptor activity, Fig 1C, arrow) became evident on the
ERG tracing of LV-RPE65-treated eyes whereas it was undetect-
able for LV-GFP-treated eyes (Fig 1C). The positive effect of LV-
RPE65 injection on rod sensitivity was clearly correlated with the
efficiency of gene transfer (Fig 1D). The limited number of eyes
expressing RPE65 (Fig 1D) is mainly due to the difficulty of the
injection in P5 pups as we already noticed in our previous study
[13]. Indeed, in our hands, this type of injection has a 30% success
rate.
We previously showed restoration of cone function after RPE65
gene transfer using Rpe65-/- Gnat1-/- mice [13]. In order to
demonstrate cone functional rescue after RPE65-gene transfer in
Rpe65R91W/R91W mice as well, we attempted to use the same
strategy using lentiviral vector injection in Rpe65R91W/R91W mice
with a rod deficiency background. As we demonstrated that rods
compete cones for 11-cis supply in the Rpe65R91W/R91W mice [28]
and might thus decrease the efficiency of gene transfer-mediated
cone rescue, we undertook lentiviral treatment in Rpe65R91W/R91W
Rho-/- mice which should minimize this phenomenon thanks to the
Cone Protein Re-Expression
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absence of the rhodopsin protein. However, so far, our P5
injections could not restore a convincing photopic response as
measured by ERGs 3 weeks post injection (data not shown).
Early LV-RPE65 treatment in Rpe65R91W/R91W mice
protects cones
To examine the extent of cone rescue after Rpe65 gene transfer
at P5, we performed immuno-histochemical analysis at the final
point of the experiment of 4 months post injection. In untreated
Rpe65R91W/R91W mice of 4 months of age, the different cone
markers S-opsin (Fig 2E,F, [28]), M/L-opsin [28] and GNAT2
were strongly reduced (Fig 2G,H, [28]) compared to wild type
animals (Fig 2A–D). As described in the literature, deprivation of
11-cis retinal affects S-opsin cellular localization and the remaining
cones expressing this protein at this age presented a mislocalized
labeling all along the cell body (Fig 2E, arrow) and at synaptic
endings (Fig 2E, arrowhead). Similar patterns of expression were
observed in LV-GFP-treated animals (Fig 2I–L). However, in the
region of wt Rpe65 gene transfer, a clear expression and correct
localization of these markers in the cone outer segments was
Figure 1. Lentiviral-mediated Rpe65 gene transfer at P5 in Rpe65R91W/R91W mice improved retinal sensitivity in scotopic conditions.
(A,B) Graphs representing the b-wave amplitudes of scotopic ERGs versus the intensity of the stimuli 1 month (A) and 4 months post injection (B) of
Rpe65R91W/R91W mice treated at P5 showed an improved sensitivity of the response in the group of animals treated with LV-RPE65 (squares) compared
to the group treated with LV-GFP (triangles). The response of the LV-RPE65 group was determined by the average response of eyes showing a
positive RPE65 labeling (n = 3). Statistical analysis using an ANOVA for repeated measurements showed significant group, stimuli intensity and group
versus stimuli intensity effects, p,0.01. For comparison, the scotopic response of age-matched wt animals (SV129) is shown (diamonds). Data are
represented as mean 6 standard error of the mean (SEM). (C) Representative ERG tracings of age-matched WT, LV-RPE65-treated and LV-GFP-treated
eyes 4 months post injection at P5 illustrate the improvement of the scotopic response of LV-RPE65-treated eyes. Note the increase in the a-wave as
well (arrow). The black vertical lines crossing the ERG tracings represent the stimulus time. (D) Plotting the b-wave threshold, corresponding to the
lowest stimulus which induces an ERG response, to the transgene expression area shows that the improved b-wave threshold correlates with RPE65
expression. LV-RPE65-treated animals (diamonds) without noticeable transgene expression present a threshold similar to the average of age-matched
untreated animals (triangle).
doi:10.1371/journal.pone.0016588.g001
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demonstrated (Fig 2M–P). Quantification of the number of cells
positive for these markers in the central section of the transduced
area of three eyes with the largest transduction area revealed
statistically significant differences between the LV-RPE65 group
(S-opsin: 4666% of wild type, GNAT2: 3466% of wild type) and
the LV-GFP (S-opsin: 664% of wild type, GNAT2: 461% of wild
type) or untreated groups (S-opsin: 1461% of wild type, GNAT2:
761% of wild type) (p,0.01, Fig 3A). The improvement in the S-
opsin labeling was possible because the transduced region was
central or even ventral in those eyes. However, a fourth eye with a
limited transduction in the dorsal region showed little increase in
the S-opsin cells because normal S-opsin expression is minimal in
this region. Moreover, the number of GNAT2 (Fig 3B) and S-
opsin (data not shown) labeled cells positively correlated to the size
of transduced area.
Furthermore, we determined the density of cones in the center
of the transduced area for 3 eyes using the GNAT2 marker which
is expressed in both S- and M/L-cones. For each treated region,
we expressed the cone density as a percentage of wild type cone
densities, determined at the same eye position in an average of 3 to
4 wt control eyes. Thus we can reliably evaluate the efficiency of
cone rescue for each eye with regards to the location of the
transduced region. This method allowed to assess efficiency of the
rescue at the site of wt gene expression and to avoid
underestimation of this effect because of the limited transduced
area (in the best case 20% of the retina). This quantification shows
that LV-RPE65 totally rescues the pattern of GNAT2 expression
with a density identical to wild type while untreated mice
(determined at the same location) presented only 23% of the wild
type GNAT2-cone density (Fig 3C).
Figure 2. LV-RPE65 injected at P5 protects cones up to 4 months post injection. (A–D) In wild type mice, S-opsin (red) and GNAT2 (green)
expressions are localized to outer segments. (E,F) In 4-month-old untreated Rpe65R91W/R91W mice, S-opsin is highly mislocalized in the cone
photoreceptors and the labeling shows distinctly cell bodies (in red, arrow) and feet (in red, arrowhead) of cones. (G,H) At the same age, the cone
transducin labeling (GNAT2 in green) is strongly reduced with only minor signals in some tips of shortened outer segments (star). (I,J) Similarly to
untreated animals, LV-GFP-injected Rpe65R91W/R91W mice show reduced and mislocalized expression of S-opsin (red, arrow), even in the region of GFP
expression (green). (K,L) The strong reduction of GNAT2 labeling (red, star) is also evident in the LV-GFP-treated region (GFP in green). (M,N) On the
contrary, after LV-RPE65 injection at P5, in the region of RPE65 expression (green), strong S-opsin expression is observed in cone outer segments (red)
while in the region devoid of WT RPE65 expression there is evidence of S-opsin mislocalization to the cell body (arrow) and synaptic termini
(arrowhead). (O,P) RPE65 gene transfer also rescues GNAT2 expression (green) in cone outer segments in the region of RPE65 expression (red).
GNAT2: cone-specific transducin a-subunit; S-opsin: short wavelength cone opsin; the scale bar indicated in A represents 50 mm for A-P.
doi:10.1371/journal.pone.0016588.g002
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LV-RPE65 treatment in adult Rpe65R91W/R91W mice
improves retinal function
We previously showed that Rpe65 gene transfer at post natal day
5 in the Rpe65 knockout model allows to protect cone survival and
function [13]. In contrast, the treatment of Rpe65-/- at 1 month of
age does not allow cone rescue despite a good expression of the
therapeutic Rpe65 gene in RPE [13]. Our present study aimed to
determine whether in Rpe65R91W/R91W mice, which show a milder
cone degeneration [27], intervention at a later stage still allows
preservation of cone photoreceptors. We performed subretinal
injections of LV-RPE65 in 1 month-old Rpe65R91W/R91W mice.
The retinal electrical activity was recorded 1 and 3 months post-
injection by ERG. As observed with the treatment at P5, LV-
RPE65-treated eyes displayed a clear increase in the sensitivity of
the scotopic b-wave 1 month post injection (Fig 4A). This effect
was sustained to the end point of the analysis 3 months post
injection (Fig 4B).
Retinal function mediates visual perception but also other vision-
linked reflexes such as the pupillary light reflex (PLR). Two
components are now recognized to mediate the input for PLR: a
subpopulation of retinal ganglion cells (ipRGCs) and the photore-
ceptors. While ipRGCs are responsible for the long-lasting PLR,
photoreceptors are the source for a PLR mediated by short stimuli
[41,42]. We thus recorded the PLR induced by photoreceptors in
untreated Rpe65R91W/R91W mice, LV-RPE65 or LV-GFP mice
treated at 1 month of age using short stimuli to emphasize on
photoreceptor-dependent PLR. Each eye was stimulated alterna-
tively while both were recorded. PLR was strongly diminished in
untreated Rpe65R91W/R91W mice of 4 months of age, where only
high intensity stimuli (more than 150 lux) provoked a partial
contraction (Fig 5A, B). The LV-GFP group behaved similarly to
untreated mice (Fig 5C). Interestingly, LV-RPE65-treated mice
displayed an increase in sensitivity and PLR response was observed
with the lowest stimulus tested (from 15 lux), being around 100-fold
more sensitive compared to LV-GFP control groups (Fig 5D). Thus
gene transfer in Rpe65R91W/R91W improves sensitivity of the PLR in
concordance with the improved ERG sensitivity.
In order to demonstrate an improvement of the supply of 11-cis
retinal to the retina in the region of wt RPE65 gene transfer, we
examined whether the trafficking of rod transducin a subunit
(GNAT1) became light-dependent again. In the dark (Fig 6A) or in
the case of absence of rhodopsin signaling in Rpe65-/- mice (Fig 6C,
D), most of the protein was localized in the outer segment.
However after light exposure (2500 lux for 20 min) and activation
of the transduction cascade by excited rhodopsin, the GNAT1
protein was translocated to the rod photoreceptor cell bodies and
feet in WT animals (Fig 6B, [43]), but not in the Rpe65-/- mice
(Fig 6D). As expected, in the region protected by LV-RPE65-
mediated gene transfer that was easily recognizable with corrected
S-opsin localization (Fig 6E), there was a clear expression of
GNAT1 all along the rods after light stimulation (Fig 6F). In
contrast, GNAT1 labeling in the region of the retina devoid of wt
RPE65 expression (Fig 6G) was mainly restricted to the outer
segments (Fig 6H). Thus, GNAT1 labeling indirectly indicates
restoration of the visual cycle in the region of wt RPE65 gene
transfer.
Similarly to our previous study [13], we attempted to
demonstrate cone function rescue after LV-RPE65 gene transfer.
We thus injected at 1 month of age both Rpe65R91W/R91W Rho-/-
mice and Rpe65R91W/R91W Gnat1-/- mice which are devoid of rod
function, to isolate a potential cone functional rescue. No
convincing cone function could be recorded 3 weeks post injection
for the former or 1 and 3 months post injection for the latter mouse
model despite the preserved retinal structure of the Rpe65R91W/R91W
Gnat1-/- mice for several months (data not shown).
LV-RPE65 treatment in adult Rpe65R91W/R91W mice
rehabilitated cones in the transduced region
Animals were treated at 1 month of age and cone survival was
then assessed three months later by immunohistochemical analysis
Figure 3. LV-RPE65 treatment of Rpe65R91W/R91W mice at P5 restores cone density comparable to wild type. (A) Quantification of the
number of outer segments expressing GNAT2 or S-opsin proteins in sections positioned in the middle of the transduced area was compared between
LV-RPE65-treated, LV-GFP-treated and untreated animals. The LV-RPE65 group shows a clear improvement in the number of cells correctly expressing
these cone markers (p,0.01, stars). Data are represented as mean 6 standard error of the mean (SEM). (B) When we plot the transduced area to the
number of GNAT2-labeled outer segments, a clear correlation shows that the wider the transgene expression area, the more GNAT2-positive outer
segments. (C) Finally, we estimated the density of cones correctly expressing the GNAT2 in the outer segments in the middle of the transduced area
of LV-RPE65-treated eyes. When compared to the density of cones in wild-type animals at the same position, we observed that LV-RPE65 injection at
P5 allows to rescue 100% of the cones (p,0.001, star). Data are represented as mean 6 SEM. 4m: 4 month old.
doi:10.1371/journal.pone.0016588.g003
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of cone markers S-opsin and GNAT2. We observed that this
relatively late delivery of wild type RPE65 protein still allowed the
preservation of the expression as well as the correct localisation of
S-opsin and GNAT2 (Fig 7D–H). Quantification of S-opsin-
expressing outer segments in the entire section located in the
center of the transduced area showed no differences between LV-
RPE65 (1262% of wild type) and LV-GFP (1263% of wild type)
or untreated groups (1561% of wild type) despite the clear
topological correlation of the correct S-opsin labeling in outer
segments with the LV-RPE65 transduced area (Fig 7D, F). To
note, injections in adults mainly lead to transduction of a region
located in the dorsal hemisphere which is known to be under-
represented by S-cones. However, similar quantification of
GNAT2 labeled outer segments revealed a significant increase in
the LV-RPE65 group (1963% of wild type) compared to the LV-
GFP (761% of wild type) or untreated groups (1361% of wild
type) (p,0.01). As these quantifications ignore the size of the
transduced area which directly affects the absolute number of
positive cells per section, we quantified the density of cones
expressing correctly the GNAT2 marker in the region of wt
RPE65 expression. With this method, the success of the rescue
corresponded to 64% of the wild type density (Fig 7I). Even if this
latter result showed not a full rescue compared to P5 treatment
(Fig 3C), the effect of gene transfer at this time point reflects more
than only preservation of cones expressing GNAT2 at the time of
treatment. Indeed, the GNAT2 cone density of 1 month-old
untreated Rpe65R91W/R91W mice (age of the treatment) is 36% of
wild type (Fig 7I), thus treatment at 1 month restored GNAT2
correct expression in 28% additional cones that regenerated after
Rpe65 gene transfer. Moreover, in the region of wt RPE65
expression, S-opsin-positive outer segments were also GNAT2-
positive (Fig 7D–F) showing that the expression patterns of both
markers were corrected in the rescued cells. Co-expression of these
markers strongly suggests the restoration of cone ability to respond
to light.
Discussion
The major finding of this study is that RPE65 gene transfer, and
a concomitant 11-cis-retinal supply, allowed revitalization of cones
that had lost their expression of phototransduction proteins and
showed an altered expression of cone outer segment markers. The
conclusion is the indication of a specific cell state during the
degeneration course that can be targeted for rehabilitation toward
a healthy cell state. The consequences of this observation are
important for the clinical application aspect of the treatments
targeting cone cells. First these results can be directly translated to
gene therapy in RPE65 patients bearing the R91W mutation.
Second, this study contributes to the general understanding of
cone degeneration following 11-cis deprivation that occurs in
several diseases due to chromophore deficiency. Both outcomes
are discussed below.
The proof of principle of RPE65 gene replacement was
previously clearly established in RPE65-null animals and has
already lead to clinical trials [2–5]. However the types of mutation
encountered in patients are heterogeneous and are often missense
mutations [22]. Residual RPE65 activity may account for the
clinical variability observed between the phenotypes [23–26] and
could have a consequence on gene transfer efficiency. First, after
gene transfer in a missense mutation background, the wild type
protein (derived from the transgene) has to compete with the
mutated forms, which are in place since early development, in
order to achieve its function. Depending on the residual properties
of the mutated proteins, interactions with partners, or the
availability of the substrate may differ from natural heterozygosity,
where both protein types cohabit since the beginning of their
expression. This hypothesis is highly unlikely with the RPE65
R91W mutant due to its extremely low level of expression
compared to the wild type protein (Fig S1C, [27]). Cell
responsiveness to a therapeutic intervention may also be altered
by a context of long-term mutant homozygosity. Second, the
Figure 4. LV-RPE65 injection in 1 month-old Rpe65R91W/R91W mice improves retinal function. (A,B) Retinal function was assessed by ERG in
dark-adapted conditions in Rpe65R91W/R91W mice 1 month (A) and 3 months (B) post injection at 1 month of age of either LV-RPE65 or LV-GFP.
Improved sensitivity was noticed for the LV-RPE65 group compared to the LV-GFP group. ANOVA for repeated measures showed for both time points
significant group, stimuli intensity and group versus stimuli intensity effects, p,0.01. Data are represented as mean 6 SEM.
doi:10.1371/journal.pone.0016588.g004
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natural course of cone degeneration is different between patients
and has to be assessed as precisely as possible to establish the optimal
intervention time. These concerns were approached using a
lentiviral-mediated RPE65 gene transfer into the Rpe65R91W/R91W
mice which are homozygous for a mutation encountered in patients
suffering from early-onset retinal degeneration [27].
We demonstrated that, consistently with the results obtained
with the Rpe65-/- mice [13], early injection of the therapeutic
vector (at P5) improves visual function and supports cone survival
to a wild type level by 4 months of age. We confirmed that
treatment at 1 month improves scotopic ERG sensitivity as well.
This effect is coherent with the improvement of scotopic ERG
observed after gene transfer in adult Rpe65-deficient mice which
are more severely affected than Rpe65R91W/R91W mice [9,11,13].
Interestingly, we also found evidence of an improvement in the
photoreceptor-mediated PLR, indicating that the brain visual
pathway implicated in PLR is at least able to drive pupil response
and can be recruited after gene transfer at 1 month of age. This
observation is consistent with previous studies showing residual
activity of the visual pathway implicated in PLR [44,45], in
cortical projections [46,47]or in the optomotor reflex [48] even in
the more severely affected RPE65 null background. The presence
of the R91W mutated protein does therefore not impair retina
functional improvement following RPE65 gene transfer.
Evidence that the visual cycle was restored after Rpe65 gene
transfer also comes from our immunohistological studies. First,
light exposure induces translocation of GNAT1 from the outer
segments to the rod cell bodies as a mechanism of light adaptation
[43,49]. This indicates that photons has been captured and
induced the phototransduction processes. This phenomenon is
only possible if the phototransduction cascade is initiated by a
receptive rhodopsin protein containing the 11-cis-retinal chromo-
phore. Thus, as expected in the region of increased 11-cis-retinal
production due to gene transfer, a clear translocation of GNAT1
following light exposure is observed in rods (Fig 6). Secondly,
mislocalization of the S-opsin protein was demonstrated to be a
consequence of 11-cis-retinal deprivation and to lead to cone
degeneration [27,30,31]. Consistent with the strong decrease in
the level of 11-cis-retinal, Rpe65R91W/R91W mice suffer from S-opsin
mislocalization at 1 month of age with a concomitant decrease in
the number of S-opsin-positive cells with time [28]. At 4 months of
age, the endpoint of our experiment, the number of S-opsin-
Figure 5. Pupillary light reflex (PLR) is improved after LV-RPE65 injection. PLR was measured following stimulation with increasing light
intensities from 15 lux to 1500 lux. Each eye was independently and sequentially stimulated with 50 ms white stimuli (represented by vertical bars on
the graphs) every 5 s. The pupil contraction was recorded and the diameter was plotted versus the time. (A) The average of 4 pupil responses of 1
month-old WT mice showed that eyes respond to even the lower stimulus tested without a noticeable increase of the amplitude of contraction with
increasing intensity of stimuli. (B) The pupil responses from 5 eyes of 4 month-old Rpe65R91W/R91W mice were averaged and showed a severe loss of
sensitivity at this age for Rpe65R91W/R91W animals. (C) The average pupil response recorded for 6 eyes injected at 1 month of age with LV-GFP shows
poor pupil light reflex 3 months post injection. (D) The average pupil response recorded for 4 eyes injected at 1 month of age with LV-RPE65 shows
improvement of the pupil light reflex 3 months post injection. Even for the lowest stimuli applied (15 lux), a pupil contraction is evident.
doi:10.1371/journal.pone.0016588.g005
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positive cones corresponded to only 16% of the wild type level
(personal data, [28]). After treatment either at P5 or at 1 month, in
the transduced area, S-opsin was re-localized to the outer segments
confirming that gene transfer induced sufficient production of 11-
cis-retinal to correct the trafficking of the S-opsin protein. These
observations show that, the increased production of 11-cis-retinal
due to the successful RPE65 gene transfer had an impact on both
rod and cone visual cells.
In 1 month-old Rpe65R91W/R91W mice 36% of the wild type
cones still expressed the GNAT2 cone-specific protein. Interest-
ingly, when animals were treated at this time point, Rpe65 gene
transfer reduced cone loss and allowed a cone preservation of up
to 64% of the wild type level at 4 months of age. Such rescue was
not observed in Rpe65-/- mice (where only 3% of the cones still
express the GNAT2 marker at 1 month of age, unpublished data)
demonstrating a prolonged therapeutic window in the
Rpe65R91W/R91W model. The success of cone rescue after gene
transfer at 1 month in Rpe65R91W/R91W mice is a direct
consequence of the slower cone degeneration observed in these
mice and may have a major impact for a human application.
Indeed, this knock-in mouse model is more similar to the patients
bearing missense mutations than the Rpe65-/- mouse model [27].
These patients may thus also benefit from a longer therapeutic
window compared to patients suffering from null mutations.
The second main advance illustrated by the success of treatment
at 1 month in Rpe65R91W/R91W mice is that not only did the
intervention stop cone loss and maintain the 36% of GNAT2-
expressing cones present at this age, but 28% additional cones
were also recruited to correctly re-express the GNAT2 cone
transducin protein, or at least to restore a detectable level of the
protein. Indeed the ventral expression of the S-opsin protein is
severely impaired in the retinas of 1 month-old Rpe65R91W/R91W
mice while the expression of the GNAT2 protein is drastically
reduced both dorsally and ventrally (36% of the wild type level).
Quantitative PCR showed that S-opsin transcription is already
reduced to 43% at this age and fell to around 10% at 4 months of
age, while GNAT2 transcription slowly decreased from 80% to
40% [28]. Thus, while the S-opsin mRNA level severely drops,
GNAT2 is primarily affected at the protein level. The necessity of
light capture ability and preserved phototransduction for photo-
receptor survival is now widely accepted. Not only do mutations of
phototransduction proteins lead to retinal degeneration [50] but
they also impact on the compartimentalization of other proteins
[31,51–53]. Our work supports the notion that, similarly, the 11-
cis-retinal supply is essential for correct expression and localization
of cone proteins. Once the cone opsins are correctly expressed and
can capture light, the expression of phototransduction proteins
such as GNAT2 can be re-established. Another possibility would
be that 11-cis-retinal acts as a cofactor for the transcription of
specific genes. Whichever mechanism is implied, gene transfer at 1
month of age allowed to recover GNAT2 protein up to 3 months
post injection in 28% additional cones that had lost the GNAT2
protein expression at the time of treatment. This rescue was
associated to the normalization of S-opsin protein expression in
the same cells, as well as improvement of outer segment structures,
showing that these cells are rehabilitated to capture light, and
suggesting that cone function is restored as well.
We previously showed that restoration of the cone marker
expression correlates with the cone function state after gene
transfer using Rpe65-/- Gnat1-/- mice [13]. Unfortunately we were
unable to show a rescue of cone function so far, using either the
Rpe65R91W/R91W Rho-/- mice injected at P5 or 1 month of age, or
Figure 6. LV-RPE65 gene transfer restores light-dependent rod transducin trafficking. (A) Dark-adapted wild type mice have a high
concentration of rod transducin (GNAT1, red) in the outer segments. (B) Upon light exposure (2500 lux for 20 min), GNAT1 (red) is translocated to the
rod photoreceptor cell bodies. (C) In dark-adapted Rpe65-/- retina, GNAT1 labeling is also concentrated in the outer segments. (D) After light exposure,
translocation of GNAT1 in rod cell bodies is strongly decreased because lack of 11-cis-retinal in these mice severely impairs phototransduction. (E,F) In
Rpe65R91W/R91W mice treated with LV-RPE65 at 1 month of age, in the region of RPE65 expression easily recognizable by the correct S-opsin
localization in the cone outer segments (E, red), light exposure induced GNAT1 translocation (F, green). (G,H) However in regions devoid of RPE65
gene transfer as shown by S-opsin absence or mislocalization (H, red), GNAT1 labeling remains concentrated in rod outer segments (G, green). Scale
bar A to D: 50 mm; E to H: 100 mm.
doi:10.1371/journal.pone.0016588.g006
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the Rpe65R91W/R91W Gnat1-/- model injected at 1 month of age.
The rod degeneration induced in the Rho-/- background may
interfere with a potential cone rescue. However, the lack of cone
function recovery after P5 treatment contrasts with the study of
Pang et al. who were able to recover a significant cone function in
Rpe65-/- Rho-/- animals 4 weeks after treatment at P14 [18].
Differences in the type of vector used (ssAAV and a strong
ubiquitous promoter) or the injection procedure may explain these
discrepancies. Moreover the rod function loss occuring prior to the
gene transfer could also have a deleterious effect on the cone and
rod environment (less neurotrophic support, release of toxic
agents, etc.) in the more stable Rpe65R91W/R91W Gnat1-/- model,
thus preventing functional cone rescue. Another possibility is that,
despite the success in increasing expression of cone markers in
Rpe65R91W/R91W retinas, treatment at 1 month of age is too late to
allow cone function recovery as well. Finally, as we observed a
limited effect with the early treatment of Rpe65-/- Rho-/- mice
compared to the study of Pang et al. (2010) [18], we may also have to
improve our protocol in order to increase the dose of RPE65 re-
expression to allow a functional cone recovery in these models.
Therefore, further experiments are needed to demonstrate cone
function rescue after gene transfer in the Rpe65R91W/R91W mouse
model. The difficulty of this model is mainly due to the residual cone
activity arising from the low amount of 11-cis retinal, and to rods
which, with minute amounts of chromophore, behave as cones.
Both of these activities mask the beneficial effect of the gene therapy.
Figure 7. LV-RPE65 injection in 1 month-old Rpe65R91W/R91Wmice protects 64% of the cones. (A,B) At 4 months of age in untreated (A) and
LV-GFP- treated mice (B), residual S-opsin is seen in shorter outer segments and in cone’s cell bodies and feet. (C) GNAT2 staining is rare or even
absent in LV-GFP-treated mice on the ventral hemisphere. (D–H) Immunolabeling 3 months post injection of LV-RPE65 showed correct S-opsin (D,F:
arrow, red) and GNAT2 (E,G: arrow, green) labeling in cone outer segments in the region of RPE65 expression (H: red). Pictures (D) to (F) were taken at
a topological position in the eye similar to (A). Note in (F) that all S-opsin labeled outer segments are also GNAT2-positive (arrow, yellow). (I)
Quantification using the GNAT2 staining of cone density in the middle position of RPE65 expression area showed that gene transfer preserved 64% of
the cones compared to wild type. This rescue was significantly different from the value obtained from age-matched untreated Rpe65R91W/R91W mice
and was also significantly higher than the value obtained with Rpe65R91W/R91W mice of 1 month of age (36% of the wt) corresponding to the time of
intervention (p,0.001, star). Thus, LV-RPE65 treatment at 1 month regenerates 28% more cones that were already lacking the GNAT2 marker at 1
month of age. Data are represented as mean 6 standard error of the mean (SEM). D is a merge picture of B and C; scale bar in A–F: 50 mm.
doi:10.1371/journal.pone.0016588.g007
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The importance of 11-cis-retinal in preserving cone survival
confirms previous observations [27,28,30–32,54]. The mislocali-
zation of cone opsin is similar in other models deprived of 11-cis-
retinal (Lrat-/- [30,31], Irbp-/- [32]). However the kinetics of the
cone cell loss and the shortening of outer segments probably
depend on the severity of the mutations (complete or partial loss of
11-cis-retinal regeneration). The determination of the critical time
frame, when cones are deprived of phototransduction proteins but
can be re-mobilized to express them correctly (as shown by our
results), is an important point in order to be able to offer visual
rescue to patients. Some studies have already approached this
topic notably using measurement of the retina thickness in the
RPE65-affected patients as a criterion to determine the retinal
degeneration stage [20]. It is here of prime importance to note that
measuring the thickness of the outer nuclear layer, which reflects
the number of photoreceptor cell bodies still present in the retina,
using optical coherence tomography (OCT), is indeed a reliable
reference that can illustrate the amount of cell loss in patients.
However, the measurement of the thickness of the outer segments
which are severely affected in remaining cells deprived of correct
phototransduction proteins may lead to an underestimation of the
potential therapeutical effect. This hypothesis could be challenged
only if ‘‘ghost photoreceptors’’ negative for GNAT2 and for S-
opsin proteins can be detected by another marker allowing to
investigate the size and the potential of regeneration of the outer
segments. There is no data so far on cone gene expression during
the natural course of the disease in human but our data suggest
that a delay between cone protein defects and cone death may also
occur in the patients.
Finally our results illustrate the importance and the advantages
of animal models bearing identical mutations to those encountered
in human diseases for preclinical studies. In consequence, they also
highlight the importance of genotyping and phenotyping the
patients precisely in order to help design the appropriate models
and to collect relevant information from preclinical studies. These
data will subsequently offer the best conditions for translation to
human applications.
Materials and Methods
Ethic statement
The animals were handled in accordance with the statement of
the ‘‘Animals in Research Committee’’ of the Association for
Research in Vision and Ophthalmology, and protocols were
approved by the local institutional committee, the ‘‘Service de la
consommation et des affaires ve´te´rinaires du canton de Vaud’’
(autorisation VD#1367.3).
Lentiviral vectors
The lentiviral vectors used in this study were previously
described in Bemelmans et al. 2006 [13]. Briefly, the transgene
plasmids contain the central polypurine tract and central
termination sequence (cPPT/CTS, [55]), the R0.8 promoter
(800 bp of the human RPE65 promoter [39,40]) which drives
expression of the mouse RPE65 cDNA (LV-RPE65 vector) or the
GFP gene (LV-GFP vector), and the woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE, [56]) downstream
of the transgene.
Recombinant lentiviral particles were produced by transient
transfection of 293T cells, as previously described [38,57]. Viral
supernatants were concentrated by two successive ultracentrifu-
gations at 709000 g and 4uC for 90 minutes. Total particle
concentration of the viral stocks was estimated by quantification of
the p24 capsid protein using RETRO-TEK HIV-1 p24 Antigen
ELISA kit (ZeptoMetrixCorporation, Buffalo, NY USA) according
to the manufacturer’s instructions. In addition, infectious titers of
the LV-GFP vector were quantified by infection of 293T cells, in
which the R0.8 promoter is active, followed by flow cytometry on
a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA).
Animals and Surgical procedures
The mice were kept at 20uC under a 12 hours light/12 hours
dark cycle with light on at 7 am and fed ad libitum. The mice were
anaesthetized with volatile anaesthesia, and injections at post-natal
day 5 (P5) (intravitreously) or at 1 month of age (subretinally) were
performed as described in Bemelmans et al. 2006 [13]. For P5
treatment, 1.5 ml of viral suspension containing 140 ng or 100 ng
of p24 for LV-RPE65 and LV-GFP, respectively, were injected
per eye, while for 1 month treatment the same dose was injected
but in 2 ml of viral suspension per eye. After surgery, 0.5 mg/ml of
paracetamol was added in the water of the mice for 1 day.
Electroretinogram (ERG)
ERG recordings were performed on site at Jules-Gonin Eye
Hospital as described in Bemelmans et al 2006 [13] using a
Multiliner Vision apparatus (Jaeger/Toennies, Ho¨chberg, Ger-
many) and a Ganzfeld stimulator adapted for rodent examination.
Retinal function was assessed with corneal DTL electrodes.
Amplitude of the a-wave (photoreceptor response) was defined as
the difference between the baseline level at the time of stimulation
and the peak of the a-wave. Amplitude of the b-wave (second-
order neurons) was defined as the difference between the peak of
the b-wave and the peak of the a-wave (or the baseline level when
the a-wave was not detectable). Amplitudes are expressed in
microvolts (mV).
Pupillary light reflex (PLR)
The A1000 pupillometer for small rodents was developed by
Neuroptics with the collaboration of Dr Randy Kardon (Univer-
sity of Iowa) and Dr Sinisa Grozdanic (Iowa state University)
(manuscript in preparation). The mice were anaesthetized with a
mixture of ketamine (45 mg/kg) and xylazine (17 mg/kg). A
protocol using 50 ms white light stimuli of increasing intensities
(15, 45, 150, 474 and 1500 lux) with 5 s of interval was applied
twice sequentially to the left and then to the right eye. The evoked
pupil response was recorded by two infrared cameras targeting
both pupils and the pupil diameter determined automatically by
the Neuroptics software. The averages of 4 to 6 pupil recordings
were then calculated and plotted using the Excel program.
Histology and immunolabeling
Before their sacrifice at 4 months of age, the mice injected at 1
month were dilated by topic administration of 0.5% tropicamide +
10% neosynephrine (1: 1) and exposed for 20 min to 2500 lux in
cages covered with aluminium foil to increase translocation of the
rod transducin to the rod cell body. After sacrifice, the mouse eyes
were cauterized at the nasal corner of the eye, enucleated, the
corneas were perforated and eyes were fixed for 1 hour in 4% PFA
in PBS. After overnight incubation in 30% sucrose, the eyes were
embedded based on the cauterization mark in albumin from hen
egg white (Fluka, Buchs, Switzerland) in order to provide sections
with both a dorsal and a ventral hemisphere, and cut in 14 mm
sections using a cryostat. Sections were collected on six serial slides
for each eye allowing multiple labeling throughout the entire eye
for each slide.
The antibodies against GNAT2, S-opsin, RPE65 and GFP and
the immunohistological conditions were already described in
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Bemelmans et al. 2006 [13]. Rabbit anti-GNAT1 (Santa Cruz) was
used at 1:2000, overnight at 4uC. Secondary antibodies, goat anti-
rabbit linked to Alexa 488 (1:4000, Invitrogen, Carlsbad, CA,
USA) or to Cy5 (1:500, F(ab) fragment, Jackson Immunoresearch,
Newmarket, England), were incubated for 1 hour at room
temperature. For co-labeling of both polyclonal antibodies anti-
RPE65 (Pin5) and anti-GNAT2, anti-RPE65 was first incubated
overnight and well washed before incubation for 6 hours at room
temperature with anti-rabbit-Cy5 F(ab) fragments to saturate the
epitopes [58]. Then we proceeded with the standard protocol for
GNAT2 staining.
Quantifications in the transduced areas of GNAT2 and S-opsin
were performed as previously described [13]. In order to obtain
the ratio to the wild type for each treated eye, we averaged
GNAT2 and S-opsin countings of corresponding sections (using
section of the same position in the eye on the nasal-temporal axis)
of 3 to 4 different wild type eyes as control values. Densities of
GNAT2-labeled outer segments were determined by the average
density at a given location on a section, for 3 sections located in the
center of the transduced area (most transversal sections). Densities
of the identical location on 3 similarly positioned sections of wild
type retinas of were averaged as controls. Similar quantifications
were performed in 1 month- and 4 month-old untreated
Rpe65R91W/R91W mice.
Statistical analysis
Statistical analyses of the electroretinograms were done using
StatViewH 5.0 software. Histological counting of cone markers was
analyzed by one way-ANOVA to determine the statistical
significance between the different groups (LV-RPE65 treated,
LV-GFP treated, untreated Rpe65R91W/R91W).
Supporting Information
Figure S1 Lentiviral-mediated Rpe65 gene transfer in
the retina. (A) Injection of LV-RPE65 at P5 allowed expression
of the wt RPE65 in the RPE (labeled in green). (B) Injection of LV-
GFP occasionally led to GFP expression in Mu¨ller cells (labeled in
green). (C) Subretinal injection of LV-RPE65 in 1-month old
Rpe65R91W/R91W mice also induced expression of the wt RPE65
protein (labeled in red). The limit of staining between the faint
R91W mutant protein detection and the strong WT RPE65
expression is indicated by an arrow. (D) The transduced area was
comparable between P5 and 1 month injections. The heteroge-
neity observed is due to the surgical procedure. RPE: retinal
pigment epithelium; OS: outer segment; ONL outer nuclear layer
(photoreceptor nuclei); the scale bar indicated in A represents
50 mm for A and B and 200 mm for C.
(TIF)
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